Rhythm Pharmaceuticals Inc (RYTM)
$43.76
+2.78
(+6.78%)▲
Insights on Rhythm Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 6 quarters, 4.28M → 24.23M (in $), with an average increase of 27.3% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -51.82M → -41.63M (in $), with an average increase of 7.6% per quarter
Performance
- $42.09$43.96$43.76
3.82%
Downside
Day's Volatility :4.25%
Upside
0.45%
- $15.50$52.57$43.76
64.58%
Downside
52 Weeks Volatility :70.52%
Upside
16.76%
Returns
| Period | Rhythm Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -4.85% | -1.1% | 0.0% |
6 Months | 61.54% | 10.5% | 0.0% |
1 Year | 162.19% | 5.4% | 0.5% |
3 Years | 124.07% | 14.4% | -21.1% |
Highlights
Market Capitalization | 2.3B |
Book Value | $2.86 |
Earnings Per Share (EPS) | -3.2 |
Wall Street Target Price | 59.0 |
Profit Margin | -238.52% |
Operating Margin TTM | -170.28% |
Return On Assets TTM | -32.22% |
Return On Equity TTM | -85.1% |
Revenue TTM | 77.4M |
Revenue Per Share TTM | 1.34 |
Quarterly Revenue Growth YOY | 175.7% |
Gross Profit TTM | 21.5M |
EBITDA | -182.6M |
Diluted Eps TTM | -3.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.14 |
EPS Estimate Next Year | -2.07 |
EPS Estimate Current Quarter | -0.7 |
EPS Estimate Next Quarter | -0.7 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 34.83%
Technicals Summary
Sell
Neutral
Buy
Rhythm Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Rhythm Pharmaceuticals Inc | 7.94% | 61.54% | 162.19% | 124.07% | 124.07% |
 Moderna, Inc. | 21.5% | 73.44% | -8.79% | -23.24% | 361.25% |
 Regeneron Pharmaceuticals, Inc. | 1.52% | 14.97% | 25.57% | 98.37% | 178.01% |
 Novo Nordisk A/s | -2.23% | 21.74% | 50.76% | 232.25% | 415.39% |
 Vertex Pharmaceuticals Incorporated | -1.37% | 3.97% | 15.22% | 87.53% | 129.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Rhythm Pharmaceuticals Inc | NA | NA | NA | -4.14 | -0.85 | -0.32 | NA | 2.86 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Rhythm Pharmaceuticals Inc | Buy | $2.3B | 124.07% | NA | -238.52% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
Institutional Holdings
Goldman Sachs Group Inc
16.79%PRIMECAP Management Company
13.39%Baker Bros Advisors LP
10.64%BlackRock Inc
10.56%RA Capital Management, LLC
8.86%Vanguard Group Inc
5.37%
Corporate Announcements
Rhythm Pharmaceuticals Inc Earnings
Rhythm Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
Organization | Rhythm Pharmaceuticals Inc |
Employees | 226 |
CEO | Dr. David P. Meeker M.D. |
Industry | Health Technology |
Discover More
Royalty Pharma Plc
$43.76
+6.78%
Grupo Aeroportuario Del Sureste, Sabdecv
$43.76
+6.78%
Roku, Inc.
$43.76
+6.78%
Stag Industrial, Inc.
$43.76
+6.78%
Janus Henderson Group Plc
$43.76
+6.78%
Crane Nxt Co
$43.76
+6.78%
Construction Partners Inc-a
$43.76
+6.78%
Plains Gp Holdings, L.p.
$43.76
+6.78%
Vanguard Ultra Short Bond Et
$43.76
+6.78%